Inhibition of herpes simplex virus type 1 by the experimental immunosuppressive agent leflunomide.
about
Current and potential treatments for ubiquitous but neglected herpesvirus infectionsLeflunomide: a drug with a potential beyond rheumatologyInhibition of pyrimidine biosynthesis pathway suppresses viral growth through innate immunityOccurrence of HSV-1-induced pneumonitis in patients under standard immunosuppressive therapy for rheumatic, vasculitic, and connective tissue disease.A comprehensive review of immunosuppression used for liver transplantation.Leflunomide inhibition of BK virus replication in renal tubular epithelial cells.Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis.Identification of broad-spectrum antiviral compounds and assessment of the druggability of their target for efficacy against respiratory syncytial virus (RSV)Current and future immunosuppressive strategies in renal transplantation.Polyomavirus-associated nephropathy: update on antiviral strategies.A review of antiviral drugs and other compounds with activity against feline herpesvirus type 1Leflunomide prevents alveolar fluid clearance inhibition by respiratory syncytial virusLeflunomide in renal transplantation.Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms.The human polyomavirus BK (BKPyV): virological background and clinical implications.Immunosuppressive drug therapy.Effect of Leflunomide, Cidofovir and Ciprofloxacin on replication of BKPyV in a salivary gland in vitro culture system.Clinical Pharmacokinetic Monitoring of Leflunomide in Renal Transplant Recipients with BK Virus Reactivation: A Review of the Literature.Treatment of Theiler's virus-induced demyelinating disease with teriflunomide.Leflunomide in the Treatment of a Pseudotumoral Genital Herpes Simplex Virus Infection in an HIV Patient.Immunosuppressive effects and mechanisms of leflunomide in dengue virus infection of human dendritic cells.The inhibitors of nucleotide biosynthesis leflunomide, FK778, and mycophenolic acid activate hepatitis B virus replication in vitro.Prospective, pilot, open-label, short-term study of conversion to leflunomide reverses chronic renal allograft dysfunction.Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection.Thrombin enhances herpes simplex virus infection of cells involving protease-activated receptor 1.Concurrent antiviral and immunosuppressive activities of leflunomide in vivo.FK506, a secondary metabolite produced by Streptomyces, presents a novel antiviral activity against Orthopoxvirus infection in cell culture.A genome-wide siRNA screen identifies a druggable host pathway essential for the Ebola virus life cycle
P2860
Q27023452-20A2397D-BB75-4991-A64D-5F677A5230F0Q28294236-47F63D02-E03A-4A8F-9759-DF9B16440B11Q28534057-5FA7C71F-AFBE-4DE2-BDB5-269B62489874Q33446433-1426B2C4-6E70-463E-A78F-24D632189768Q33602527-624A4C6D-900B-4EC2-A527-9C68A116FB3CQ33614540-24BBED9F-333D-48A5-9220-81D9A26AA761Q34805086-954AA218-1607-49F0-AA74-B8498FA4C2C6Q34881218-8054379B-E945-4DFB-8505-DFE95608F712Q35906315-002B3301-D777-4CFD-8857-76223D3C7C50Q36492418-12036168-3E4D-4A39-8101-E0FC88E82451Q37059841-97985C84-10CA-474C-B8FE-6509A3F4C6C5Q37144432-F6095BA0-BEB5-4DFC-9DE3-4A0FD63BF955Q37877256-1767EB9B-3D44-4634-B957-45CDA796B7B6Q38061056-B3CB0F68-59AA-4C8D-802B-B81EF84E01D1Q38115582-57451DEB-6999-412C-9351-18C31754BA49Q38134066-83FF50A1-0A59-4641-BFCE-92658E8C3638Q39103226-5A6A0C7E-4A25-4D97-9C48-13587CB36F09Q39155699-8FE53B48-8B17-4749-A088-FB3DCD845695Q40039485-2DAFECC1-0DF4-48FD-9B60-D896226A636EQ40259798-DCAB9E33-F34A-4C8A-91CA-697BB73FA8C8Q40315102-406B1182-2EE9-4E31-AFF1-712F92B92A52Q42633382-8525D442-4C85-4531-BE08-45F6DDD44EB6Q43749375-AFDAE5C1-9ABC-4EDE-985E-B3AA68B8272DQ45111047-FFA51310-1BA3-4314-8A51-06AFD9C9280FQ45404654-A71982DB-A0DC-42AD-87BE-86A2446324C5Q46909270-98494FA5-22E9-46A0-A5D3-71F3E277B1C6Q50734762-A544C96F-FE14-4ED3-869E-090873DF75B1Q56906441-2EDCEE41-4609-40AA-9736-F91BD3E7EA22
P2860
Inhibition of herpes simplex virus type 1 by the experimental immunosuppressive agent leflunomide.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Inhibition of herpes simplex v ...... suppressive agent leflunomide.
@ast
Inhibition of herpes simplex v ...... suppressive agent leflunomide.
@en
type
label
Inhibition of herpes simplex v ...... suppressive agent leflunomide.
@ast
Inhibition of herpes simplex v ...... suppressive agent leflunomide.
@en
prefLabel
Inhibition of herpes simplex v ...... suppressive agent leflunomide.
@ast
Inhibition of herpes simplex v ...... suppressive agent leflunomide.
@en
P2093
P1433
P1476
Inhibition of herpes simplex v ...... suppressive agent leflunomide.
@en
P2093
Dierksheide JE
Hejmanowski AQ
Waldman WJ
Williams JW
P304
P356
10.1097/00007890-200101150-00031
P577
2001-01-01T00:00:00Z